This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/drugbank/drug/DB00407/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00407/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00407/identifier/drugbank/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n20http://www.drugs.com/mtm/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00407/identifier/chemspider/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00407/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00407/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00407
rdf:type
n3:Drug
n3:description
Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.
n3:group
approved withdrawn
n3:halfLife
Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose.
n3:indication
For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
n3:manufacturer
n10:271B458A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00407 n15:DB00407
dcterms:title
Ardeparin
adms:identifier
n6:772 n7:46505194 n14:PA164754878 n16:Ardeparin n17:751 n18:DB00407
n3:mechanismOfAction
Ardeparin binds to antithrombin III, accelerating its activity in inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity versus anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity.
n3:toxicity
Symptoms of overdose may include excessive bleeding and bruising.
n8:hasAHFSCode
n9:92-00-00 n9:20-12-04-16
foaf:page
n20:ardeparin.html
n3:IUPAC-Name
n4:271B458F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4595-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4594-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4591-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4592-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4593-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B45A4-363D-11E5-9242-09173F13E4C5 n4:271B458D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B458E-363D-11E5-9242-09173F13E4C5 n4:271B458B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B458C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B459B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B459C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4596-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4597-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4599-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4598-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B459A-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed following subcutaneous administration, with a mean bioavailability of 92% (based on anti-factor Xa activity).
n3:affectedOrganism
Humans and other mammals
n3:category
n3:Bioavailability
n4:271B45A0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B45A2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B45A3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B459F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B459E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B45A1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4590-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B459D-363D-11E5-9242-09173F13E4C5